Background: After decades of irradiation as standard therapy for clinical stage I testicular seminoma, alternative treatment approaches have emerged including postorchiectomy surveillance and adjuvant chemotherapy. This study was performed to assess a dual policy of surveillance and selective single-agent carboplatin (for high-risk cases) in a multicenter setting. From 1994From to 1999 patients with stage I seminoma were included. Sixty (29.6%) were considered poor-risk cases (i.e. with vascular invasion and/or pathological tumor stage pT2 or greater) and received two courses of adjuvant carboplatin, whereas 143 (70.4%) without risk criteria underwent close surveillance.
Introduction
Testicular germ-cell cancer is a model for curable malignancy, with an overall survival rate of 90-95% when considering all stages. Current therapeutic trials are aimed at maintaining these favorable results while reducing treatment-related toxicity, particularly in non-advanced disease [1] . Until recently, irradiation to the ipsilateral pelvic and para-aortic nodes was the standard therapy for patients with stage I seminoma after orchiectomy. Reported relapse rates have ranged from 3% to 5%, and seminoma deaths occur in about 2% of cases [2] . However, a small but significant increased risk for second malignancies and peptic ulcers with this treatment approach has been confirmed. In addition, recent improvements in clinical staging (particularly high-resolution computed tomography scanning) have made stage I seminoma a rather different disease from that whose 60% relapse rate led to use of prophylactic radiotherapy nearly 30 years ago.
Alternative treatment options have been investigated in this patient subset, including surveillance [3] and adjuvant chemotherapy [4] . Although no randomized clinical trial has been published yet, long-term patient survival does not seem to be compromised in comparison with traditional irradiation. How-ever, surveillance is associated with relapse rates of 15-20% (most of them can be salvaged with chemotherapy or irradiation), considerable psychological stress and incremental costs. On the other hand, adjuvant chemotherapy with single-agent carboplatin, although generally well tolerated, implies treating all patients with stage I seminoma, while 80% of them are thought to be cured with orchiectomy.
In 1994, the Spanish Germ Cell Cancer Cooperative Group (GG) designed a protocol to evaluate a dual treatment policy for stage I seminoma in which only high-risk patients (with an expected relapse rate >20%) were assigned to adjuvant carboplatin whereas the remainder (whose expected relapse rate is <15%) were managed with surveillance. If this strategy was feasible, most patients would be preserved from postorchiectomy treatment and the relapse rate both on surveillance and after chemotherapy would be significantly decreased. Mature results of this protocol are presented here. The objective of this study was to assess the following: (i) the percentage of patients needing adjuvant chemotherapy; (ii) the relapse rate in patients treated with either carboplatin or surveillance; and (iii) long-term overall and disease-free survival rates in both groups.
Patients and methods
Patients with histologically proven pure seminoma, clinical stage I disease and resection margins free of tumor were included in this study after orchiectomy performed at any of the GG centers. Routine staging consisted of clinical history, physical examination, chest X-ray films, computed tomography (CT) of abdomen and pelvis, ultrasonography of the contralateral testicle, whole blood cell counts, serum chemistries including lactate dehydrogenase, α-fetoprotein (AFP) and β-human chorionic gonadotropin (BHCG). Patients with UICC (1987 edition) tumor stage pT2 or greater (i.e. tumors infiltrating albuginea, epididymis, spermatic cord or scrotum) [5] [6] . Tumor relapses in both groups were treated primarily with etoposide and cisplatin chemotherapy (E400P) [7] .
Potential prognostic factors for relapse were prospectively recorded, including patient age (≤30 years versus >30 years), tumor diameter (≤40 mm versus >40 mm), histological subtype (classical versus anaplastic), pT stage (pT1 versus pT2-4), vascular invasion, rete testis invasion and preoperative BHCG levels (negative versus positive). Histological features were reviewed locally. Overall survival (OS) and disease-free survival (DFS) were estimated from the date of orchiectomy with the Kaplan-Meier method [8] . Comparison of resulting curves and univariate analysis of prognostic factors were performed with the log-rank test [9] . Ninety-five per cent confidence intervals (95% CI) are given when appropriate.
Results
From January 1994 to June 1999, 203 cases were included in 202 patients (one patient with a bilateral seminoma was registered twice) from 29 centers. Median patient age was 35 years (range 15-81) and median of maximum tumor diameter was 44 mm (range 10-120). One hundred and ninety-nine patients underwent inguinal orchiectomy, two underwent scrotal orchiectomy and one had abdominal surgery for an undescended testicle. Preoperative serum BHCG levels were positive (i.e. >5 mU/ml) in 30 cases (14.8%) (median 32 mU/ml; range 10-3730). By definition, all patients were pre-and postorchiectomy AFP negative, and postorchiectomy BHCG negative. Sixty patients (29.6%) with risk factors received two courses of carboplatin, whereas 143 (70.4%) were managed with surveillance. Main patient characteristics and distribution of prognostic factors among treatment arms are summarized in Table 1 .
Median time from orchiectomy to chemotherapy start was 37 days (range 9-70). Time interval between courses was 21, 28 and 35 days in four, 50 (86%) and four cases, respectively. All treatment delays were due to asymptomatic myelotoxicity. No dose reductions were performed. Except for emesis, no episodes of grade 3-4 adverse events were noted. Chemotherapy toxicity is summarized in Table 2 . At least 20 patients (10%) are known to have fathered after treatment (13 on surveillance, seven after carboplatin).
At the time of the present analysis, median follow-up time was 52 months (range 14-92), with 164 patients (80%) being followed for >3 years and only five patients (2.5%) being lost to follow-up. Relapses were observed in two (3.3%) patients treated with adjuvant carboplatin and in 23 (16.1%) patients on surveillance. Five-year DFS was 87.3% (95% CI 82.5% to 92%) for all patients, 83.5% (95% CI 77.2% to 89.8%) for those on surveillance and 96.6% (95% CI 92% to 100%) for chemotherapy-treated cases ( Figure 1 ). Median time to relapse for patients with tumor recurrences was 11 months (range 3.9-39.6). Relapses were located mainly in the retroperitoneum (84%), whereas one case each presented in mesenteric nodes (this patient had received a transcrotal orchiectomy), pelvis, lung and as serum BHCG increase. Only two cases (8%) relapsed with symptoms of disease, the rest being detected through routine CT scans (76%) or increase in serum BHCG levels (16%). Median tumor size at relapse was 32.5 mm (range 0-60). All patients were rendered disease-free with chemotherapy (four cases with three courses of classic BEP, 18 cases with four courses of E400P), irradiation (two cases) or surgery (one case).
However, four patients (2%) died of causes unrelated to seminoma or its treatment: one traffic accident, one heroine overdose, one hepatic cirrhosis and one non-Hodgkin's lymphoma. Four patients (2%) had second germ-cell malignancies: two metachronous non-seminomatous germ-cell tumors, one synchronous and one metachronous testicular seminomas. One other patient developed acute leukemia. These latter five patients with second malignancies are living disease-free. Of note, all six malignancies in this series occurred in patients on surveillance. Five-year OS was 96.7% (95% CI 92.8% to 100%) and cause-specific OS was 100%. A univariate analysis of prognostic factors for DFS was performed. In the whole series, only adjuvant therapy (favoring carboplatin versus surveillance, P = 0.0142) reached statistical significance. No predictive features could be identified in patients on surveillance, whereas positive serum preoperative BHCG levels were of adverse prognostic value (P = 0.0064) in patients treated with adjuvant carboplatin. However, in all groups, younger age was associated with a non-significant increased risk of recurrence. Table 3 depicts the distribution of relapses among prognostic categories.
Discussion
Approximately 75% of patients with testicular seminoma present with stage I disease at diagnosis. Over the past 30 to 40 years, standard treatment of these patients involved radical inguinal orchiectomy and routine adjuvant radiation therapy with 25-30 Gy to the retroperitoneal and ipsilateral pelvic lymph nodes. The results of this modality have been excellent, with more than 2600 patients being reported from 1980 to 1994, consistent long-term DFS rates of 96% and OS rates of 98% [2] . However, recent concerns about a 6-9% incidence of peptic ulcers [10] and especially a two-to three-fold increased risk of second malignancies in irradiated fields [11, 12] have resulted in the evaluation of alternative therapies. The first of these attempts has been the successful reduction of either the radiation doses or the radiation fields [13] . However, it is becoming increasingly evident that radiation therapy to all stage I seminoma patients may represent overtreatment. In fact, amounting experience with postorchiectomy surveillance has demonstrated that nearly 80% of these patients can expect to be cured without adjuvant treatment, and almost all recurrences can be successfully rescued. The development of imaging of retroperitoneal nodes with CT has allowed a more accurate assessment of disease extent and evaluation of treatment results, and has facilitated follow-up evaluation on surveillance programs. More than 900 patients managed by this approach have already been reported since 1990 [3, [14] [15] [16] , with 5-year DFS rates of 80-85% and OS approaching 100%. The disadvantages of clinical surveillance are incremental costs, need of patient compliance to the follow-up protocol, psychological stress and the chance of late relapses [17] . A third treatment option is adjuvant chemotherapy with singleagent carboplatin. To date, nearly 550 patients so treated have been reported [4, [18] [19] [20] . Acute toxicity is mild and long-term side-effects have not been described. Moreover, 5-year DFS is 97-100%, with a 100% cause-specific OS. However, once again, all patients being treated need to show a disease with very good prognosis. An ongoing phase III randomized study (MRC-TE19) is comparing adjuvant radiotherapy with a single cycle of carboplatin, although recent experience suggests that two chemotherapy courses are more effective [18] . To our knowledge, this is the first report evaluating a dual policy of postorchiectomy surveillance and selective adjuvant chemotherapy for stage I seminoma. Our results suggest that this schedule is feasible in a nationwide multicenter setting, and longterm results are equivalent to those achieved with other modalities (i.e. no seminoma-related mortality was seen). Considering patients treated with adjuvant chemotherapy and after tumor relapse, 120 of 203 cases (59.1%) were safely preserved from any form of therapy. With only two of 60 relapses (3.3%), we confirm two courses of carboplatin as an effective adjuvant treatment even for patients with high-risk criteria. Moreover, it seems evident that starting chemotherapy within 10 days after orchiectomy is not mandatory [18] [19] [20] . The main limitation of this study was the absence of universally accepted prognostic factors for relapse in patients managed by surveillance at the time of its design. In a single center experience, tumor diameter, microvascular invasion and age reached statistical significance [21] . In the Royal Marsden Hospital series of 103 patients managed by surveillance, the only significant prognostic factor for relapse was the presence of lymphatic and/or vascular invasion (9% versus 17% relapse rate) [15] . More recently, in a joint study with 638 patients from three large series of surveillance, only tumor size and rete testis invasion entered the multivariate prognostic model [22] . We chose pTNM and vascular invasion because of its widespread use and general acceptance [23] . However, a 16.1% relapse rate on surveillance (similar to that expected in unselected stage I patients) makes us question the predictive value of our criteria. None of the prognostic factors studied in this report achieved statistical significance; a fact that could be related to the small number of events (relapses) and/or the impact of selective adjuvant chemotherapy. Thus, in 1999 the Spanish GG started a second dual policy study using the new selection criteria (tumor size >40 mm and rete testis invasion) [22] , employing carboplatin with the more adequate area-under-the-curve (AUC 7) dosing, and using a 21-day interval between cycles.
We have not specifically addressed other important issues such as long-term carboplatin toxicity, fertility, quality of life aspects and economic costs both on surveillance and after carboplatin because all of them were investigated in previous studies [3, 4, [14] [15] [16] [17] [18] [19] . However, it is noteworthy that we observed in this series six second malignancies (four of them germ-cell tumors), but none of them occurred in the group treated with carboplatin. Then, a protective effect of chemotherapy against a second contralateral testicular tumor (in comparison with surgery alone) can not be ruled out, as suggested by Oliver et al. [4] . The simplification of treatment according to our multicenter protocol means that there would be reduced referral of early stage testis cancer to specialist centers to discriminate between high-and low-risk patients. Although our simplified surveillance policy seems adequate, it should be possible to minimize costs by further increasing the intervals for follow-up investigations.
In conclusion, although there is need for improvement, this dual treatment policy for patients with stage I seminoma is feasible, preserves 70% of cases from adjuvant treatment (and 59% from any form of postorchiectomy therapy) without compromising longterm results, and it could be used as a risk-adapted alternative to irradiation, surveillance and carboplatin.
